文献速递临床试验与 GCP流行病学与生物统计

乳腺癌无病生存随机试验中样本量重新估计后的随访

Follow up after sample size re-estimation in a breast cancer randomized trial for disease-free survival.
PubMed 文献 · Trials · 2019-08-23

该研究回顾性评估了一项由美国国立卫生研究院资助的国际辅助乳腺癌治疗随机试验中盲法样本量重新估计(SSRE)的实施情况。比较重新估计时、原计划及最终揭盲后的对照组失败概率,并评估增加受试者与否对最终结果的影响。结果显示重新估计程序在估计对照组失败概率方面表现尚可,原计划队列与全部随机队列的风险比接近。

要点

  • 盲法SSRE估计的3年对照组失败概率0.24、5年0.40,与揭盲后SSRE队列的3年0.22、5年0.33相近。
  • 原计划队列HR 1.25(0.86,1.79)与全部随机队列HR 1.24(95%CI 0.91,1.68)接近,增加受试者未明显改变治疗效应估计。
  • 作者认为对于时间-事件结局,预先计划的盲法SSRE程序可能是维持检验效能的最佳选择。

核心结论

  • 该盲法样本量重新估计程序在重新估计时对对照组失败概率的估计表现尚可;对于时间-事件结局,预先计划的盲法SSRE程序可能是维持检验效能的最佳选择。

研究设计与样本

  • 回顾性评估一项国际、美国国立卫生研究院资助的辅助乳腺癌治疗随机试验中的盲法样本量重新估计程序,试验注册号NCT00201851,于2005年9月9日注册,为回顾性注册。
  • 比较SSRE时估计的对照组失败概率与原计划假设、SSRE队列最终揭盲估计及最终总对照组估计。
  • 评估原计划队列(n=340)与加入重新估计后新增受试者后的全部随机队列(n=509)的最终治疗组间比较。

主要发现

  • 盲法SSRE时估计的3年对照组失败概率为0.24、5年为0.40;揭盲后SSRE队列3年失败概率为0.22(0.16,0.30)、5年为0.33(0.26,0.41)。
  • 原计划队列治疗效应HR为1.25(0.86,1.79),全部随机队列HR为1.24(95%CI 0.91,1.68);两组风险比接近,且95%CI均跨1,未达统计学显著。
  • 原计划队列与全部随机患者在对照组随时间变化的失败概率及总风险比上差异很小。

临床怎么用

  • 作者认为对于时间-事件结局,预先计划的盲法SSRE程序可能是维持检验效能的最佳选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While the clinical trials and statistical methodology literature on sample size re-estimation (SSRE) is robust, evaluation of SSRE procedures following the completion of a clinical trial has been sparsely reported. In blinded sample size re-estimation, only nuisance parameters are re-estimated, and the blinding of the current trial treatment effect is preserved. Blinded re-estimation procedures are well-accepted by regulatory agencies and funders. We review our experience of sample size re-estimation in a large international, National Institutes of Health funded clinical trial for adjuvant breast cancer treatment, and evaluate our blinded sample size re-estimation procedure for this time-to-event trial. We evaluated the SSRE procedure by examining assumptions made during the re-estimation process, estimates resulting from re-estimation, and the impact on final trial results with and without the addition of participants, following sample size re-estimation. METHODS: We compared the control group failure probabilities estimated at the time of SSRE to estimates used in the original planning, to the final un-blinded control group failure probability estimates for those included in the SSRE procedure (SSRE cohort), and to the final total control group failure probability estimates. The impact of re-estimation on the final comparison between randomized treatment groups is evaluated for those in the originally planned cohort (n = 340) and for the combination of those recruited in the originally planned cohort and those added after re-estimation (n = 509). RESULTS: Very little difference is observed between the originally planned cohort and all randomized patients in the control group failure probabilities over time or in the overall hazard ratio estimating treatment effect (originally planned cohort HR 1.25 (0.86, 1.79); all randomized cohort HR 1.24 95% CI (0.91, 1.68)). At the time of blinded SSRE, the estimated control group failure probabilities at 3 years (0.24) and 5 years (0.40) were similar to those for the SSRE cohort once un-blinded (3 years, 0.22 (0.16, 0.30); 5 years, 0.33 (0.26, 0.41)). CONCLUSIONS: We found that our re-estimation procedure performed reasonably well in estimating the control group failure probabilities at the time of re-estimation. Particularly for time-to-event outcomes, pre-planned blinded SSRE procedures may be the best option to aid in maintaining power. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00201851 . Registered on 9 September 2005. Retrospectively registered.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hade EM, Young GS, Love RR, et al. Follow up after sample size re-estimation in a breast cancer randomized trial for disease-free survival. Trials. 2019. PMID: 31443726. doi:10.1186/s13063-019-3632-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。